Diamyd Medical to present at Precision Medicine conference

CEO Ulf Hannelius has been invited to give a talk at the “Precision medicine – From patient to lab and back again” conference organized by the Copenhagen Bioscience Cluster, a Novo Nordisk foundation initiative.

The talk, which is based on an abstract submitted to the conference entitled “Developing data-driven precision therapies for Type 1 diabetes”, will focus on how the data collected in Diamyd Medical’s clinical trials together with scientific advances in the field have informed the development of the precision medicine diabetes vaccine Diamyd® for the treatment of type 1 diabetes. The conference will be held digitally May 2nd to 6th

More information about the conference can be found here: https://cph-bioscience.com/en/events/cbc21-2may2021

About Diamyd Medical
Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication on April 21, 2021, 12.00 CET.


  PDF version